Book chapter
Acute Myelogenous Leukemia
Tumor Board Review, pp.477-492
Springer Publishing Company, Incorporated, Third edition
2023
DOI: 10.1891/9780826145987.0030
Abstract
Acute myeloid leukemia (AML) accounts for about 90% of all acute leukemias. AML is diagnosed when the blast percentage is more than 20% in the peripheral blood or bone marrow, however; patients with t (8;21), inv (16), t(16;16), and t(15;17) are diagnosed with AML regardless of blast count. Karyotyping, immunophenotyping, and molecular testing are important steps in diagnosis as results impact prognosis and treatment. Standard induction chemotherapy for medically fit patients is “7+3” which is 7 days of infusional cytarabine and 3 days of anthracycline. A bone marrow biopsy is done after induction to check response to treatment. Consolidation chemotherapy is typically with high dose cytarabine followed by allogeneic or autologous transplant for intermediate-risk and unfavorable risk patients. In recent years, new drugs and targeted therapies have been approved for induction and for relapsed AML. These new therapeutic opportunities have improved outcomes in elderly and high-risk AML patients.
Details
- Title: Subtitle
- Acute Myelogenous Leukemia
- Creators
- Elizabeth F EisenmengerMaria Siddiqui - University of Iowa, Internal MedicineGustavo Rivero
- Contributors
- Martha Pritchett Mims (Editor)Helen K Chew (Editor)Francis P Worden (Editor)
- Resource Type
- Book chapter
- Publication Details
- Tumor Board Review, pp.477-492
- Edition
- Third edition
- DOI
- 10.1891/9780826145987.0030
- Publisher
- Springer Publishing Company, Incorporated; New York, NY
- Language
- English
- Date published
- 2023
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984848502602771
Metrics
1 Record Views